# An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)

> **NCT02354846** · — · UNKNOWN · sponsor: **Yonsei University** · enrollment: 112 (estimated)

## Conditions studied

- B-cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02354846
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354846, "An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02354846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*